Treatment with PD-L1 antibodies reverses this process by uncoupling the PI3K/AKT-mTOR enhancement, thus restoring autophagic activity and alleviating pulmonary fibrosis (Lu et al., 2022). Here, AKT1 is linked to pulmonary fibrosis.